| 1.34 -0.05 (-3.6%) | 07-26 15:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.68  |
1-year : | 8.23 |
| Resists | First : | 4.86 |
Second : | 7.05 |
| Pivot price | 2.17 |
|||
| Supports | First : | 1.34 |
Second : | 1.11 |
| MAs | MA(5) : | 1.53 |
MA(20) : | 2.26 |
| MA(100) : | 3.6 |
MA(250) : | 4.76 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 1 |
D(3) : | 1.7 |
| RSI | RSI(14): 32.4 |
|||
| 52-week | High : | 28.69 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NEXI ] has closed above bottom band by 17.3%. Bollinger Bands are 96.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.39 |
| Low: | 1.32 - 1.33 | 1.33 - 1.34 |
| Close: | 1.32 - 1.34 | 1.34 - 1.35 |
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Fri, 12 Jul 2024
NEXI Stock Alert: NexImmune Delists From Nasdaq - InvestorPlace
Thu, 11 Jul 2024
What Is Going on With NexImmune (NEXI) Stock Today? - InvestorPlace
Tue, 09 Jul 2024
PNC Financial Services Group Inc. Sells 303,399 Shares of NexImmune, Inc. (NASDAQ:NEXI) - Defense World
Wed, 07 Feb 2024
NexImmune Faces Critical Funding Crisis, Mulls Liquidation - TipRanks
Tue, 09 Jan 2024
NexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation - InvestorPlace
Wed, 03 Jan 2024
Dear NEXI Stock Fans, Mark Your Calendars for Jan. 18 - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 17 (%) |
| Held by Institutions | 11.1 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 12 (K) |
| EPS | -24.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -69.8 % |
| Return on Equity (ttm) | -196.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -15.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.06 |
| PEG Ratio | 0 |
| Price to Book value | 0.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|